Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

Trudell Medical International announces BPA free AEROCHAMBER PLUS* FLOW-VU* Chambers

Trudell Medical International is pleased to announce that AEROCHAMBER PLUS* FLOW-VU* anti-static Valved Holding Chambers are Bisphenol A Free. As always, the AEROCHAMBER PLUS* FLOW-VU* Chambers also remain free of Phthalates, Latex, Lead and PVC (Polyvinyl chloride). Trudell has recognized that consumers are beginning to voice their desire for more BPA Free products.

17 Mar 2010

Compugen announces validation of IDD discovery platform for identification of cell penetrating peptides

Compugen Ltd. announced today the development and validation of its Intracellular Drug Delivery (IDD) discovery platform for identification of cell penetrating peptides. Compugen also announced that as part of the validation process for the new platform, more than twenty novel peptides, predicted and selected in silico, demonstrated the predicted cell penetrating properties in initial experimental validation studies.

17 Mar 2010

Generex Biotechnology's proprietary buccal insulin spray product presented at CODHy Congress

Generex Biotechnology Corporation (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that Philip Raskin, MD, of The University of Texas Southwestern Medical Center in Dallas, Texas, made a presentation in respect of Generex Oral-lyn™, the Company's proprietary buccal insulin spray product, at The Latin America Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension held in Buenos Aires, Argentina, March 11-14, 2010 (www.comtecmed.com/Codhy/argentina).

17 Mar 2010

Quinnova Pharmaceuticals introduces NEOSALUS CREAM for chronic inflammatory skin conditions

Quinnova Pharmaceuticals, Inc., a specialty pharmaceutical company that develops and markets novel topical delivery platform-based prescription drugs, announced the launch of its NEOSALUSTM CREAM. NEOSALUS CREAM, the latest addition to Quinnova’s NEOSALUS brand, is a prescription product with anti-inflammatory properties that can be used without age or long-term use restrictions for the treatment of a variety of chronic inflammatory skin conditions like atopic dermatitis, contact dermatitis, and hand eczema.

16 Mar 2010

Nuvo Research commences enrollment in WF10 Phase 2 clinical trial for allergic rhinitis

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced that it has enrolled the first patient in its European Phase 2 clinical trial evaluating WF10 as a treatment for allergic rhinitis.

16 Mar 2010

Lilly receives exclusive rights to commercialize Acrux's testosterone solution

Eli Lilly and Company and Acrux announced today that they have entered into an exclusive worldwide license agreement for the potential commercialization of Acrux's experimental underarm testosterone solution (proposed tradename AXIRON™).

16 Mar 2010

Impax Laboratories initiates challenge of patent over generic TRILIPIX

Impax Laboratories, Inc. today confirms that it has initiated a challenge of the patent listed by Abbott Laboratories and Fournier Laboratories Ireland Ltd. in connection with its TRILIPIX® (choline fenofibrate) delayed-release capsules, 135 mg and 45 mg.

15 Mar 2010

Ranbaxy resolves generic Actos patent litigation

Ranbaxy Laboratories Limited, along with its wholly owned subsidiary Ranbaxy Pharmaceuticals Inc. (collectively, "Ranbaxy"), announced today that they have reached an agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Ranbaxy's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15 mg, 30 mg and 45 mg tablets.

15 Mar 2010

A.P. Pharma reports net loss of $1.9M for fourth-quarter of 2009

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its fourth quarter and full year ended December 31, 2009.

15 Mar 2010

New PEGylated Polylysine dendrimers: Benefits patients with cancer, HIV and lymphatic conditions

Monash Institute of Pharmaceutical Science researchers, in collaboration with the biotechnology company Starpharma Holdings Ltd have developed a new method to deliver medications that may benefit thousands of patients with particular types of cancer, HIV and lymphatic conditions world-wide.

15 Mar 2010

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

Bio-Path Holdings, Inc., a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today that the U.S. Food and Drug Administration has allowed an IND (Investigational New Drug) for the Company’s lead cancer drug candidate liposomal Grb-2 to proceed into clinical trials.

15 Mar 2010

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

BeaconEquity.com announces an investment report featuring biotechnology company BioSante Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

12 Mar 2010

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2009.

12 Mar 2010

StockPreacher.com announces investment report featuring Generex Biotechnology

StockPreacher.com announces an investment report featuring Generex Biotechnology Corp. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Mar 2010

BeaconEquity.com announces investment report featuring NexMed

BeaconEquity.com announces an investment report featuring NexMed Inc. (Nasdaq:NEXM). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

12 Mar 2010

Development of promising new cancer therapies: OICR announces $1M investment

Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced an investment of $1 million towards the development of two new promising cancer therapies.

12 Mar 2010

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

ACCESS PHARMACEUTICALS, INC. announced that it has received reports of significant bioavailability of orally delivered insulin in two independently-conducted animal studies. The studies, which confirm earlier findings, were performed as part of on-going work with commercial collaborators that are evaluating Access' Cobalamin™ Oral Drug Delivery Technology.

12 Mar 2010

Generic Focalin XR patent suit: Intellipharmaceutics International announces settlement

Intellipharmaceutics International Inc. today announced that Novartis Pharmaceuticals Corporation and Celgene Corporation have settled their patent suit in the U.S. District Court for the District of New Jersey, and Elan Pharma International Ltd. has settled its patent suit in the U.S. District Court for the District of Delaware, with Intellipharmaceutics Corp., a wholly-owned subsidiary of Intellipharmaceutics International, and its licensee Par Pharmaceutical, Inc. over a generic version of the Attention Deficit Hyperactivity Disorder drug Focalin XR® (dexmethylphenidate hydrochloride).

12 Mar 2010

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.

11 Mar 2010

Columbia Laboratories' fourth-quarter 2009 net revenues up 21%

Columbia Laboratories, Inc. today reported financial results of the three- and twelve-months periods ended December 31, 2009.

11 Mar 2010

Drug Delivery News and Research

Further Reading

Trudell Medical International announces BPA free AEROCHAMBER PLUS* FLOW-VU* Chambers

Compugen announces validation of IDD discovery platform for identification of cell penetrating peptides

Generex Biotechnology's proprietary buccal insulin spray product presented at CODHy Congress

Quinnova Pharmaceuticals introduces NEOSALUS CREAM for chronic inflammatory skin conditions

Nuvo Research commences enrollment in WF10 Phase 2 clinical trial for allergic rhinitis

Lilly receives exclusive rights to commercialize Acrux's testosterone solution

Impax Laboratories initiates challenge of patent over generic TRILIPIX

Ranbaxy resolves generic Actos patent litigation

A.P. Pharma reports net loss of $1.9M for fourth-quarter of 2009

New PEGylated Polylysine dendrimers: Benefits patients with cancer, HIV and lymphatic conditions

Bio-Path Holdings' liposomal Grb-2 IND receives FDA clearance to proceed into clinical trials

BeaconEquity.com: BPAX incurs net loss of $6.4M for quarter ended September 30, 2009

Halozyme Therapeutics reports net loss of $12.7M for fourth-quarter of 2009

StockPreacher.com announces investment report featuring Generex Biotechnology

BeaconEquity.com announces investment report featuring NexMed

Development of promising new cancer therapies: OICR announces $1M investment

Independently-conducted studies confirm significant bioavailability of orally delivered insulin

Generic Focalin XR patent suit: Intellipharmaceutics International announces settlement

Watson Pharmaceuticals' TRELSTAR receives FDA approval for treatment of advanced prostate cancer

Columbia Laboratories' fourth-quarter 2009 net revenues up 21%

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News